Immunterapi til patienter med malignt melanom og hjernemetastaser

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Immunterapi til patienter med malignt melanom og hjernemetastaser. / Simonsen, Line Thing; Schmidt, Anne Mette Sjørslev; Øllegaard, Trine Heide; Svane, Inge Marie; Bastholt, Lars; Luczak, Adam Andrzej; Schmidt, Henrik.

I: Ugeskrift for Laeger, Bind 181, Nr. 24, V01190057, 2019.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Simonsen, LT, Schmidt, AMS, Øllegaard, TH, Svane, IM, Bastholt, L, Luczak, AA & Schmidt, H 2019, 'Immunterapi til patienter med malignt melanom og hjernemetastaser', Ugeskrift for Laeger, bind 181, nr. 24, V01190057. <https://ugeskriftet.dk/videnskab/immunterapi-til-patienter-med-malignt-melanom-og-hjernemetastaser>

APA

Simonsen, L. T., Schmidt, A. M. S., Øllegaard, T. H., Svane, I. M., Bastholt, L., Luczak, A. A., & Schmidt, H. (2019). Immunterapi til patienter med malignt melanom og hjernemetastaser. Ugeskrift for Laeger, 181(24), [V01190057]. https://ugeskriftet.dk/videnskab/immunterapi-til-patienter-med-malignt-melanom-og-hjernemetastaser

Vancouver

Simonsen LT, Schmidt AMS, Øllegaard TH, Svane IM, Bastholt L, Luczak AA o.a. Immunterapi til patienter med malignt melanom og hjernemetastaser. Ugeskrift for Laeger. 2019;181(24). V01190057.

Author

Simonsen, Line Thing ; Schmidt, Anne Mette Sjørslev ; Øllegaard, Trine Heide ; Svane, Inge Marie ; Bastholt, Lars ; Luczak, Adam Andrzej ; Schmidt, Henrik. / Immunterapi til patienter med malignt melanom og hjernemetastaser. I: Ugeskrift for Laeger. 2019 ; Bind 181, Nr. 24.

Bibtex

@article{684537e0f1944fe8b58d9879d595dcb3,
title = "Immunterapi til patienter med malignt melanom og hjernemetastaser",
abstract = "Melanoma has a high propensity to form brain metastases, and in this review, we discuss the treatment options for brain metastases. These have previously been sparse, but with the introduction of targeted therapy and checkpoint inhibitors, studies including patients with brain metastases have been published. Recent studies investigating combination of either dabrafenib and trametinib or ipilimumab and nivolumab have proved promising. Based on phase II studies, the most effective treatment for patients with asymptomatic brain metastases seems to be ipilimumab and nivolumab. Symptomatic brain metastases are presently being further investigated.",
author = "Simonsen, {Line Thing} and Schmidt, {Anne Mette Sj{\o}rslev} and {\O}llegaard, {Trine Heide} and Svane, {Inge Marie} and Lars Bastholt and Luczak, {Adam Andrzej} and Henrik Schmidt",
year = "2019",
language = "Dansk",
volume = "181",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "24",

}

RIS

TY - JOUR

T1 - Immunterapi til patienter med malignt melanom og hjernemetastaser

AU - Simonsen, Line Thing

AU - Schmidt, Anne Mette Sjørslev

AU - Øllegaard, Trine Heide

AU - Svane, Inge Marie

AU - Bastholt, Lars

AU - Luczak, Adam Andrzej

AU - Schmidt, Henrik

PY - 2019

Y1 - 2019

N2 - Melanoma has a high propensity to form brain metastases, and in this review, we discuss the treatment options for brain metastases. These have previously been sparse, but with the introduction of targeted therapy and checkpoint inhibitors, studies including patients with brain metastases have been published. Recent studies investigating combination of either dabrafenib and trametinib or ipilimumab and nivolumab have proved promising. Based on phase II studies, the most effective treatment for patients with asymptomatic brain metastases seems to be ipilimumab and nivolumab. Symptomatic brain metastases are presently being further investigated.

AB - Melanoma has a high propensity to form brain metastases, and in this review, we discuss the treatment options for brain metastases. These have previously been sparse, but with the introduction of targeted therapy and checkpoint inhibitors, studies including patients with brain metastases have been published. Recent studies investigating combination of either dabrafenib and trametinib or ipilimumab and nivolumab have proved promising. Based on phase II studies, the most effective treatment for patients with asymptomatic brain metastases seems to be ipilimumab and nivolumab. Symptomatic brain metastases are presently being further investigated.

M3 - Tidsskriftartikel

C2 - 31267950

VL - 181

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 24

M1 - V01190057

ER -

ID: 238526523